Literature DB >> 15319273

Decreased brain dopaminergic transporters in HIV-associated dementia patients.

Gene-Jack Wang1, Linda Chang, Nora D Volkow, Frank Telang, Jean Logan, Thomas Ernst, Joanna S Fowler.   

Abstract

HIV has a propensity to invade subcortical regions of the brain, which may lead to a subcortical dementia termed HIV-cognitive motor complex. Therefore, we aimed to assess whether dopamine (DA) D2 receptors and transporters (DAT) are affected in the basal ganglia of subjects with HIV, and how these changes relate to dementia status. Fifteen HIV subjects (age 44.5 +/- 11 years; CD4 185 +/- 130/mm3)) and 13 seronegative controls (42 +/- 12 years) were evaluated with PET to assess availability of DAT ([11C]cocaine) and DA D2 receptor ([11C]raclopride). HIV patients with associated dementia (HAD), but not those without dementia (ND) had significantly lower DAT availability in putamen (-19.3%, P = 0.009) and ventral striatum (-13.6%, P = 0.03) compared with seronegative controls. Higher plasma viral load in the HIV dementia patients correlated with lower DAT in the caudate (r = -0.7, P = 0.02) and putamen (r = -0.69, P = 0.03). DA D2 receptor availability, however, showed mild and non-significant decreases in HIV patients. These results provide the first evidence of DA terminal injury in HIV dementia patients, and suggest that decreased DAT may contribute to the pathogenesis of HIV dementia. The greater DAT decrease in the putamen than in the caudate parallels that observed in Parkinson's disease. The inverse relationship between viral burden and DAT availability further supports HIV-mediated neurotoxicity to dopaminergic terminals.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15319273     DOI: 10.1093/brain/awh269

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  123 in total

1.  Increased dopaminergic neurotransmission in therapy-naïve asymptomatic HIV patients is not associated with adaptive changes at the dopaminergic synapses.

Authors:  C Scheller; G Arendt; T Nolting; C Antke; S Sopper; M Maschke; M Obermann; A Angerer; I W Husstedt; F Meisner; E Neuen-Jacob; H W Müller; P Carey; V Ter Meulen; P Riederer; E Koutsilieri
Journal:  J Neural Transm (Vienna)       Date:  2010-05-09       Impact factor: 3.575

2.  Methamphetamine-induced behavioral and physiological effects in adolescent and adult HIV-1 transgenic rats.

Authors:  Marley D Kass; Xiangqian Liu; Michael Vigorito; Linda Chang; Sulie L Chang
Journal:  J Neuroimmune Pharmacol       Date:  2010-06-09       Impact factor: 4.147

Review 3.  The role of medical imaging in defining CNS abnormalities associated with HIV-infection and opportunistic infections.

Authors:  David F Tate; Rola Khedraki; Daniel McCaffrey; Daniel Branson; Jeffrey Dewey
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

Review 4.  Neurotoxicity of human immunodeficiency virus-1: viral proteins and axonal transport.

Authors:  Italo Mocchetti; Alessia Bachis; Valeriya Avdoshina
Journal:  Neurotox Res       Date:  2011-09-27       Impact factor: 3.911

5.  Adolescent HIV-1 transgenic rats: evidence for dopaminergic alterations in behavior and neurochemistry revealed by methamphetamine challenge.

Authors:  Landhing M Moran; Michael Y Aksenov; Rosemarie M Booze; Katy M Webb; Charles F Mactutus
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

6.  Preferential sensitivity of human dopaminergic neurons to gp120-induced oxidative damage.

Authors:  Shuxian Hu; Wen S Sheng; James R Lokensgard; Phillip K Peterson; R Bryan Rock
Journal:  J Neurovirol       Date:  2009-09       Impact factor: 2.643

7.  Neurotoxicity of HIV-1 Tat protein: involvement of D1 dopamine receptor.

Authors:  Janelle M Silvers; Marina V Aksenova; Michael Y Aksenov; Charles F Mactutus; Rosemarie M Booze
Journal:  Neurotoxicology       Date:  2007-07-22       Impact factor: 4.294

Review 8.  Genetic, transcriptomic, and epigenetic studies of HIV-associated neurocognitive disorder.

Authors:  Andrew J Levine; Stella E Panos; Steve Horvath
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-01       Impact factor: 3.731

9.  [3H]Dopamine Uptake through the Dopamine and Norepinephrine Transporters is Decreased in the Prefrontal Cortex of Transgenic Mice Expressing HIV-1 Transactivator of Transcription Protein.

Authors:  Matthew Strauss; Bernadette O'Donovan; Yizhi Ma; Ziyu Xiao; Steven Lin; Michael T Bardo; Pavel I Ortinski; Jay P McLaughlin; Jun Zhu
Journal:  J Pharmacol Exp Ther       Date:  2020-05-27       Impact factor: 4.030

10.  A Gap in Time: Extending our Knowledge of Temporal Processing Deficits in the HIV-1 Transgenic Rat.

Authors:  Kristen A McLaurin; Landhing M Moran; Hailong Li; Rosemarie M Booze; Charles F Mactutus
Journal:  J Neuroimmune Pharmacol       Date:  2016-10-03       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.